SequelSEC

Acumen Pharmaceuticals, Inc. ABOS

Biological Products, (No Diagnostic Substances) · CIK 0001576885 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$123.83M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

Acumen Pharmaceuticals, Inc. (ABOS) reported net income of -$121.34M for the fiscal year ended 2025-12-31. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from Acumen Pharmaceuticals, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Acumen Pharmaceuticals, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$123.83M-$114.02M-$61.14M-$45.24M-$19.58M-$7.91M
Net income-$121.34M-$102.33M-$52.37M-$42.86M-$100.61M-$7.32M
Research & development$104.88M$93.80M$42.32M$32.36M$12.30M$8.00M
Weighted-average diluted sharesshares 60.56Mshares 60.01Mshares 48.61Mshares 40.60Mshares 20.06MUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$0$0$0$0$0$0
Diluted EPS$-2.00$-1.71$-1.08$-1.06$-5.02Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$18.95M$20.22M$18.82M$12.88M$7.28M$1.35M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Acumen Pharmaceuticals, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Cash & equivalents$53.99M$35.63M$66.89M$130.10M$122.16M$43.78M
Total assets$122.83M$238.99M$310.12M$196.59M$230.33M$44.43M
Current assets$122.25M$178.31M$246.62M$180.33M$198.66M$44.43M
Total liabilities$52.40M$57.18M$43.15M$7.81M$5.15M$6.37M
Current liabilities$30.01M$27.61M$12.97M$7.81M$5.15MUnavailable
Total equity incl. NCI$70.43M$181.82M$266.97M$188.78M$225.18M-$18.59M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailable$56.65M
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt$22.40M$29.42M$29.90M$0UnavailableUnavailable
Accounts payable$554.00K$5.65M$1.38M$1.64M$1.09M$531.00K

Cash flow

Acumen Pharmaceuticals, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Operating cash flow-$115.54M-$86.22M-$43.06M-$35.15M-$17.96M-$7.45M
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flow$133.93M$48.03M-$171.67M$39.18M-$104.12MUnavailable
Financing cash flow-$34.00K$6.93M$151.75M$3.91M$200.47M$44.68M
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Stock-based compensation$9.85M$9.64M$6.14M$3.06M$922.00K$154.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Acumen Pharmaceuticals, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio4.07x6.46x19.01x23.08x38.60xUnavailable
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equity0.32xUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ABOS in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-12View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-26View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO AMGN

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.